Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754312 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00754312 is a Phase 1 study that was terminated before completion, run by Syndax Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT00754312, a Phase 1 study, was terminated before completion, sponsored by Syndax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
Interventions
- DRUG SNDX-275
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00754312
The ClinicalTrials.gov registry entry for NCT00754312 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNDX-275 is the first listed.
NCT00754312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00754312 about?
NCT00754312 is a clinical study titled "A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer". The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
What is the current status of trial NCT00754312?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2009-02-28.
What interventions are being tested in trial NCT00754312?
The interventions under investigation include: SNDX-275 (DRUG).
Who is sponsoring clinical trial NCT00754312?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.